Pathogenic helper T cells as the novel therapeutic targets for immune-mediated intractable diseases.

[1]  T. Nakayama,et al.  Thioredoxin-interacting protein is essential for memory T cell formation via the regulation of the redox metabolism , 2023, Proceedings of the National Academy of Sciences of the United States of America.

[2]  T. Nakayama,et al.  Characterization of eosinophils and natural killer cells in nasal polyps and peripheral blood in eosinophilic chronic rhinosinusitis patients. , 2022, Allergology International.

[3]  G. Freeman,et al.  mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection , 2022, The Journal of clinical investigation.

[4]  T. Nakayama,et al.  Interleukin-33-activated neuropeptide CGRP-producing memory Th2 cells cooperate with somatosensory neurons to induce conjunctival itch. , 2022, Immunity.

[5]  T. Nakayama,et al.  Conventional and pathogenic Th2 cells in inflammation, tissue repair, and fibrosis , 2022, Frontiers in Immunology.

[6]  A. Stratigos,et al.  The JAK/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review , 2022, Journal of clinical medicine.

[7]  T. Tsukamoto,et al.  Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2–induced lung exudative vasculitis and predicts COVID-19 severity , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Y. Okamoto,et al.  Single-cell immunoprofiling after immunotherapy for allergic rhinitis reveals functional suppression of pathogenic Th2 cells and clonal conversion. , 2022, Journal of Allergy and Clinical Immunology.

[9]  A. Vatrella,et al.  Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13 , 2022, Vaccines.

[10]  Stanley B. Cohen,et al.  Oral surveillance and JAK inhibitor safety: the theory of relativity , 2022, Nature Reviews Rheumatology.

[11]  P. Sternberg,et al.  Nematode ascarosides attenuate mammalian type 2 inflammatory responses , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Nakayama,et al.  Epigenetic regulation of inflammation by CxxC domain‐containing proteins * , 2021, Immunological reviews.

[13]  Xiaoying Hu,et al.  The JAK/STAT signaling pathway: from bench to clinic , 2021, Signal Transduction and Targeted Therapy.

[14]  A. Otsuka,et al.  Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. , 2021, Allergology international : official journal of the Japanese Society of Allergology.

[15]  T. Nakayama,et al.  CD4 + T cells in inflammatory diseases : pathogenic T-helper cells and the CD69-Myl9 system. , 2021, International immunology.

[16]  A. Hirbe,et al.  TYK2 in Cancer Metastases: Genomic and Proteomic Discovery , 2021, Cancers.

[17]  A. Humbles,et al.  Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity , 2021, European Respiratory Journal.

[18]  A. Rao,et al.  Roles of TET and TDG in DNA demethylation in proliferating and non-proliferating immune cells , 2021, Genome Biology.

[19]  T. Nakayama,et al.  The Role of CD4+ Resident Memory T Cells in Local Immunity in the Mucosal Tissue – Protection Versus Pathology – , 2021, Frontiers in Immunology.

[20]  Jianxun Song,et al.  Metabolic Reprogramming and Reactive Oxygen Species in T Cell Immunity , 2021, Frontiers in Immunology.

[21]  Xiaoliang Yang,et al.  Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials. , 2021, Pharmacology & therapeutics.

[22]  T. Nakayama,et al.  Memory-type pathogenic Th2 cells and ILC2s in type 2 allergic inflammation. , 2021, Journal of Allergy and Clinical Immunology.

[23]  V. Julia,et al.  Interleukin-31 Signaling Bridges the Gap Between Immune Cells, the Nervous System and Epithelial Tissues , 2021, Frontiers in Medicine.

[24]  Eiryo Kawakami,et al.  The Cxxc1 subunit of the Trithorax complex directs epigenetic licensing of CD4+ T cell differentiation , 2021, The Journal of experimental medicine.

[25]  Y. Wan,et al.  Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy , 2021, Science Advances.

[26]  T. Nakayama,et al.  Eosinophils: Cells known for over 140 years with broad and new functions. , 2020, Allergology international : official journal of the Japanese Society of Allergology.

[27]  C. Akdis,et al.  Mechanisms of allergen-specific immunotherapy and allergen tolerance. , 2020, Allergology international : official journal of the Japanese Society of Allergology.

[28]  L. Eicher,et al.  Dupilumab for the treatment of adolescents with atopic dermatitis , 2020, Expert review of clinical immunology.

[29]  Sohita Dhillon.  Delgocitinib: First Approval , 2020, Drugs.

[30]  S. Fujieda,et al.  The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. , 2020, Allergology international : official journal of the Japanese Society of Allergology.

[31]  G. Canonica,et al.  Interleukin-5 in the Pathophysiology of Severe Asthma , 2019, Front. Physiol..

[32]  Q. Xiao,et al.  IRF-7 Is a Critical Regulator of Type 2 Innate Lymphoid Cells in Allergic Airway Inflammation. , 2019, Cell reports.

[33]  R. Lipton,et al.  Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. , 2019, The New England journal of medicine.

[34]  H. Ortega,et al.  Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma , 2019, The Journal of allergy and clinical immunology.

[35]  S. Feske,et al.  Calcium Signaling Controls Pathogenic Th17 Cell-Mediated Inflammation by Regulating Mitochondrial Function. , 2019, Cell metabolism.

[36]  Hee-Jung Choi,et al.  Increased α2-6 sialylation of endometrial cells contributes to the development of endometriosis , 2018, Experimental & Molecular Medicine.

[37]  S. Fujieda,et al.  Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death. , 2018, Blood.

[38]  Y. Okamoto,et al.  Amphiregulin‐Producing Pathogenic Memory T Helper 2 Cells Instruct Eosinophils to Secrete Osteopontin and Facilitate Airway Fibrosis , 2018, Immunity.

[39]  D. Brenner,et al.  Reactive Oxygen Species: Involvement in T Cell Signaling and Metabolism. , 2018, Trends in immunology.

[40]  B. Chipps,et al.  Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[41]  Y. Okamoto,et al.  Pathogenicity of memory Th2 cells is linked to stage of allergic rhinitis , 2018, Allergy.

[42]  C. Bachert,et al.  Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial , 2017, The Journal of allergy and clinical immunology.

[43]  K. Asano,et al.  Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus , 2017, The Journal of allergy and clinical immunology.

[44]  Hiroshi Ito,et al.  Mucus plugging in allergic bronchopulmonary aspergillosis: Implication of the eosinophil DNA traps. , 2017, Allergology international : official journal of the Japanese Society of Allergology.

[45]  James J. Lee,et al.  Sputum autoantibodies in patients with severe eosinophilic asthma , 2017, The Journal of allergy and clinical immunology.

[46]  A. Klion.  Recent advances in understanding eosinophil biology , 2017, F1000Research.

[47]  K. Tokoyoda,et al.  Crucial role for CD69 in allergic inflammatory responses: CD69‐Myl9 system in the pathogenesis of airway inflammation , 2017, Immunological reviews.

[48]  S. Yancey,et al.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis , 2017, The New England journal of medicine.

[49]  Jonathan R. Brestoff,et al.  Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch , 2017, Cell.

[50]  Y. Okamoto,et al.  Th2 Cells in Health and Disease. , 2017, Annual review of immunology.

[51]  A. Madi,et al.  The transcription factor musculin promotes the unidirectional development of peripheral Treg cells by suppressing the TH2 transcriptional program , 2017, Nature Immunology.

[52]  M. Furue,et al.  The transcription factor EPAS1 links DOCK8 deficiency to atopic skin inflammation via IL-31 induction , 2017, Nature Communications.

[53]  S. Jordt,et al.  IL-33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy , 2016, Proceedings of the National Academy of Sciences.

[54]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[55]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[56]  S. Durham,et al.  Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses. , 2016, The Journal of allergy and clinical immunology.

[57]  Y. Okamoto,et al.  Myosin light chains 9 and 12 are functional ligands for CD69 that regulate airway inflammation , 2016, Science Immunology.

[58]  M. Thiry,et al.  Lung-resident eosinophils represent a distinct regulatory eosinophil subset. , 2016, The Journal of clinical investigation.

[59]  H. Ortega,et al.  Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. , 2016, Clinical therapeutics.

[60]  S. Fujieda,et al.  Eosinophil ETosis and DNA Traps: a New Look at Eosinophilic Inflammation , 2016, Current Allergy and Asthma Reports.

[61]  G. Canonica,et al.  Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs , 2016, Current opinion in allergy and clinical immunology.

[62]  T. Dainichi,et al.  The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. , 2015, The Journal of allergy and clinical immunology.

[63]  D. Voehringer,et al.  Eosinophil-specific deletion of IκBα in mice reveals a critical role of NF-κB-induced Bcl-xL for inhibition of apoptosis. , 2015, Blood.

[64]  Y. Okamoto,et al.  Asymmetric Action of STAT Transcription Factors Drives Transcriptional Outputs and Cytokine Specificity. , 2015, Immunity.

[65]  Greg M. Delgoffe,et al.  mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation. , 2015, The Journal of clinical investigation.

[66]  Massimo Gadina,et al.  The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.

[67]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[68]  Bjoern Peters,et al.  Epigenomic analysis of primary human T cells reveals enhancers associated with TH2 memory cell differentiation and asthma susceptibility , 2014, Nature Immunology.

[69]  C. Murray,et al.  The Global Burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases , 2014, PLoS neglected tropical diseases.

[70]  G. Gleich,et al.  Electron microscopy elucidates eosinophil degranulation patterns in patients with eosinophilic esophagitis. , 2014, The Journal of allergy and clinical immunology.

[71]  A. Agarwal,et al.  Images in clinical medicine. Giant papillae in vernal keratoconjunctivitis. , 2014, New England Journal of Medicine.

[72]  C. Persson,et al.  Theirs but to die and do: primary lysis of eosinophils and free eosinophil granules in asthma. , 2014, American journal of respiratory and critical care medicine.

[73]  S. Durham,et al.  Specific immunotherapy modifies allergen-specific CD4(+) T-cell responses in an epitope-dependent manner. , 2014, The Journal of allergy and clinical immunology.

[74]  Mark E Flanagan,et al.  Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.

[75]  W. Busse,et al.  Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. , 2013, The Journal of allergy and clinical immunology.

[76]  A. Azari,et al.  Conjunctivitis: a systematic review of diagnosis and treatment. , 2013, JAMA.

[77]  M. Pellegrino,et al.  The Epithelial Cell-Derived Atopic Dermatitis Cytokine TSLP Activates Neurons to Induce Itch , 2013, Cell.

[78]  L. Nelles,et al.  Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases , 2013, The Journal of Immunology.

[79]  J. Rathmell,et al.  Metabolic regulation of T lymphocytes. , 2013, Annual review of immunology.

[80]  A. Dvorak,et al.  Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. , 2013, Blood.

[81]  P. Fallon,et al.  Helminth therapies: translating the unknown unknowns to known knowns. , 2013, International journal for parasitology.

[82]  F. Horak,et al.  Allergen‐specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[83]  Angel F. Lopez,et al.  The GM–CSF/IL‐3/IL‐5 cytokine receptor family: from ligand recognition to initiation of signaling , 2012, Immunological reviews.

[84]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[85]  Julie M Gastier-Foster,et al.  Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. , 2012, Blood.

[86]  R. Kolbeck,et al.  Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[87]  R. Maizels,et al.  Diversity and dialogue in immunity to helminths , 2011, Nature Reviews Immunology.

[88]  Yutaka Suzuki,et al.  STAT6-mediated displacement of polycomb by trithorax complex establishes long-term maintenance of GATA3 expression in T helper type 2 cells , 2010, The Journal of experimental medicine.

[89]  W. Busse,et al.  Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. , 2010, The Journal of allergy and clinical immunology.

[90]  K. Takatsu,et al.  IL-5- and eosinophil-mediated inflammation: from discovery to therapy. , 2009, International immunology.

[91]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[92]  B. Sutton,et al.  IgE in allergy and asthma today , 2008, Nature Reviews Immunology.

[93]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[94]  K. Ohta,et al.  Expression and Function of Toll-Like Receptors in Eosinophils: Activation by Toll-Like Receptor 7 Ligand 1 , 2003, The Journal of Immunology.

[95]  S. Phipps,et al.  Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. , 2003, The Journal of clinical investigation.

[96]  D. Sheppard,et al.  Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma , 2002, Nature Medicine.

[97]  W. Paul,et al.  IL‐4 secreted from individual naive CD4+ T cells acts in an autocrine manner to induce Th2 differentiation , 2002, European journal of immunology.

[98]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[99]  H. Makita,et al.  Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. , 2019, The Lancet. Respiratory medicine.

[100]  Markus Ollert,et al.  Glutathione Primes T Cell Metabolism for Inflammation. , 2017, Immunity.

[101]  Shiori Yamamoto,et al.  Eosinophil extracellular trap cell death-derived DNA traps: Their presence in secretions and functional attributes. , 2016, The Journal of allergy and clinical immunology.

[102]  J. J. van den Oord,et al.  Mass Spectrometry of Flame Figures. , 2015, Acta dermato-venereologica.

[103]  M. Pesu,et al.  Therapeutic targeting of the Jak/STAT pathway. , 2014, Basic & clinical pharmacology & toxicology.

[104]  K. Takatsu,et al.  Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. , 2009, Human antibodies.

[105]  H. Nagai,et al.  Recent advances in the development of anti-allergic drugs. , 2006, Allergology international : official journal of the Japanese Society of Allergology.